---
title: "Jinling Pharmaceutical Company Limited (000919.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/000919.SZ.md"
symbol: "000919.SZ"
name: "Jinling Pharmaceutical Company Limited"
industry: "Pharmaceuticals"
datetime: "2026-05-20T08:35:12.998Z"
locales:
  - [en](https://longbridge.com/en/quote/000919.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/000919.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/000919.SZ.md)
---

# Jinling Pharmaceutical Company Limited (000919.SZ)

## Company Overview

Jinling Pharmaceutical Company Limited, together with its subsidiaries, manufactures and sells pharmaceuticals and medical devices in China and internationally. It offers Mailuoning injection and oral solution for the treatment of thromboangiitis and arteriosclerosis obliterans, as well as cerebral and venous thrombosis; Sulifei, a ferrous succinate tablet for the prevention and treatment of iron deficiency anemia; Lentinan injection, an adjuvant therapy for the treatment of malignant tumors; and absorbable gelatin sponges for the treatment of wound bleeding and trauma hemostasis. The company also provides traditional Chinese medicines, chemical medicines, active pharmaceutical ingredients, and pharmaceutical intermediates. In addition, it engages in elderly care services, rehabilitation therapy, psychological counseling, and end-of-life care; hospital management; technical services; and healthcare investment activities.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.jlyy1999.com](https://www.jlyy1999.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: C (0.43)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 144 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -2.76% |  |
| Net Profit YoY | 222.63% |  |
| P/B Ratio | 1.11 |  |
| Dividend Ratio | 1.48% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 4224148475.42 |  |
| Revenue | 3161595341.19 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 1.55% | D |
| Profit Margin | 1.87% | C |
| Gross Margin | 21.51% | D |
| Revenue YoY | -2.76% | D |
| Net Profit YoY | 222.63% | A |
| Total Assets YoY | -0.69% | D |
| Net Assets YoY | -0.45% | D |
| Cash Flow Margin | 391.82% | A |
| OCF YoY | -2.76% | D |
| Turnover | 0.52 | C |
| Gearing Ratio | 19.36% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Jinling Pharmaceutical Company Limited",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-2.76%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "222.63%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.11",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "1.48%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "4224148475.42",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "3161595341.19",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "1.55%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "1.87%",
          "rating": "C"
        },
        {
          "name": "Gross Margin",
          "value": "21.51%",
          "rating": "D"
        },
        {
          "name": "Revenue YoY",
          "value": "-2.76%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "222.63%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-0.69%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-0.45%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "391.82%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "-2.76%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.52",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "19.36%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 71.55 | 123/215 | 233.20 | 143.51 | 132.66 |
| PB | 1.11 | 12/215 | 1.23 | 1.19 | 1.14 |
| PS (TTM) | 1.34 | 17/215 | 1.49 | 1.42 | 1.35 |
| Dividend Yield | 1.48% | 87/215 | 1.43% | 1.38% | 1.33% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/000919.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/000919.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/000919.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/000919.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**